Maropack AG – FDA 483, Feb 11, 2022
An FDA inspection of Maropack AG, a sterile pharmaceutical manufacturer in Zell, Switzerland, revealed significant deficiencies in preventing microbiological contamination of sterile drug products. The firm failed to establish and follow procedures for aseptic interventions, conduct adequate deviation investigations for out-of-limit results, and ensure the efficacy of disinfectants. Additionally, the inspection found a lack of written investigations for monitoring excursions and issues with the quality control unit's change control procedures.
ID · 48f17e2b-6753-499a-b5b2-85b83410a7b2
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.